1 00:00:00,240 --> 00:00:00,560 Foreign. 2 00:00:07,040 --> 00:00:08,880 Welcome back to Translating Proteomics. 3 00:00:09,040 --> 00:00:13,080 For this end of 2025 episode, Andreas and I will share what we've 4 00:00:13,080 --> 00:00:16,239 observed in proteomics over the course of the year and what we 5 00:00:16,239 --> 00:00:18,560 think those observations mean for the field overall. 6 00:00:19,120 --> 00:00:22,240 And whether you agree or disagree with anything you hear in 7 00:00:22,240 --> 00:00:23,720 this episode, we'd love to hear from you. 8 00:00:23,720 --> 00:00:27,860 So please share your thoughts, your reflections from the year in 9 00:00:27,860 --> 00:00:30,340 the comments and we may feature them in a future episode. 10 00:00:30,660 --> 00:00:32,900 All right, Andreas, ready to dive in? 11 00:00:33,060 --> 00:00:33,460 Yes. 12 00:00:33,460 --> 00:00:34,180 Let's get started. 13 00:00:35,140 --> 00:00:35,540 Great. 14 00:00:35,780 --> 00:00:37,940 Well, so maybe I'll start with you. 15 00:00:37,940 --> 00:00:42,580 What are for, for the year, what was your largest, largest takeaway 16 00:00:42,900 --> 00:00:47,220 either from world Hoopoe or from the field of proteomics overall? 17 00:00:48,340 --> 00:00:51,380 Yeah, I mean the, the, the, the general observations throughout 18 00:00:51,380 --> 00:00:54,740 the year and what was happening in Hoopoe, I think are 19 00:00:54,900 --> 00:00:55,700 converging. 20 00:00:56,030 --> 00:01:02,830 From my perspective, there was essentially a visible, much fewer 21 00:01:02,830 --> 00:01:07,150 posters and presentations in Toronto than maybe in previous year. 22 00:01:07,150 --> 00:01:11,350 But the posters and presentations we saw were much sharper 23 00:01:11,350 --> 00:01:15,470 in focus, more meaningful, and it was very much application driven 24 00:01:15,470 --> 00:01:15,790 research. 25 00:01:17,310 --> 00:01:23,630 The particular field that stood out for me was that over 25% 26 00:01:23,630 --> 00:01:27,160 of the posters were essentially functional translational 27 00:01:27,160 --> 00:01:28,520 proteomics applications. 28 00:01:29,240 --> 00:01:34,160 And within that series of presentations, the clinical proteomics 29 00:01:34,160 --> 00:01:35,160 took center stage. 30 00:01:35,800 --> 00:01:39,800 And within that category of clinical proteomics, immunopeptidomics 31 00:01:39,800 --> 00:01:45,080 was basically one of the main areas of highlights at hopo. 32 00:01:45,080 --> 00:01:50,280 And maybe we describe what immunopeptidomics is, but in general, 33 00:01:51,320 --> 00:01:56,410 a cell generates essentially small peptides that it presents on 34 00:01:56,410 --> 00:02:00,210 the major histocompatibility complex on the surface of the cell, 35 00:02:00,290 --> 00:02:03,410 and then the immune system essentially learns what's present 36 00:02:03,650 --> 00:02:05,090 in the cell or tissue. 37 00:02:05,970 --> 00:02:10,370 These particular peptides that are being presented are particularly 38 00:02:10,370 --> 00:02:15,290 important in the context of oncology, autoimmune diseases, but 39 00:02:15,290 --> 00:02:17,330 also in a precision medicine approach. 40 00:02:17,490 --> 00:02:21,890 So having the ability to understand what the immune system 41 00:02:21,890 --> 00:02:27,680 essentially sees is a core application of proteomics can't be 42 00:02:27,680 --> 00:02:28,880 done by any other technology. 43 00:02:29,520 --> 00:02:34,280 And it's actually a very, very nice sweet spot for high resolution 44 00:02:34,280 --> 00:02:35,160 mass spectrometry. 45 00:02:35,160 --> 00:02:41,120 And so that was very, very clear for a front runner in applications 46 00:02:41,280 --> 00:02:42,080 at hopo. 47 00:02:42,080 --> 00:02:42,800 Did you see that? 48 00:02:43,280 --> 00:02:44,160 That's interesting. 49 00:02:44,240 --> 00:02:48,640 So I mean, just to double click a little bit, it sounds like 50 00:02:48,720 --> 00:02:54,570 you saw overall a slight shift in the field from the percentage 51 00:02:54,570 --> 00:02:58,570 of posters that were purely technology focused to ones that were 52 00:02:58,570 --> 00:03:00,050 more focused on the application. 53 00:03:00,770 --> 00:03:06,090 Would you say that it is a larger percentage of folks who are 54 00:03:06,090 --> 00:03:11,010 using proteomics as a tool to answer other biological questions? 55 00:03:11,090 --> 00:03:15,250 Do you think those questions are further along now so that they 56 00:03:15,250 --> 00:03:16,050 have more to share. 57 00:03:17,760 --> 00:03:21,880 What do you attribute this change in this subtle shift in the 58 00:03:21,880 --> 00:03:22,400 field to? 59 00:03:23,360 --> 00:03:24,400 That's a great question. 60 00:03:24,560 --> 00:03:30,560 I think over a decade and a half we have seen mostly focus around 61 00:03:30,720 --> 00:03:31,120 technology. 62 00:03:32,560 --> 00:03:35,120 How do we evolve our methods development? 63 00:03:35,840 --> 00:03:40,040 And that basically is now no longer the main focus for hupo. 64 00:03:40,040 --> 00:03:41,880 There's about 10 to 15% of the posters. 65 00:03:41,880 --> 00:03:43,120 We will see new method development. 66 00:03:44,510 --> 00:03:48,350 People demonstrate that they can do that in a new context. 67 00:03:48,590 --> 00:03:52,870 But there's much more focus on true application of the technologies 68 00:03:52,870 --> 00:03:54,430 to biological questions. 69 00:03:54,430 --> 00:03:58,830 And so that's very exciting because the field itself now has, 70 00:03:59,950 --> 00:04:05,110 amongst many of the contributions, real insights, real 71 00:04:05,110 --> 00:04:06,270 biological insights. 72 00:04:06,670 --> 00:04:07,390 That's interesting. 73 00:04:07,710 --> 00:04:09,150 I'm not sure I observed that. 74 00:04:09,310 --> 00:04:12,030 I think I definitely saw a widening. 75 00:04:12,030 --> 00:04:12,990 That there were. 76 00:04:14,000 --> 00:04:18,120 There were a larger number of more biology focused studies being 77 00:04:18,120 --> 00:04:18,640 shared. 78 00:04:19,200 --> 00:04:24,000 But I think my takeaway was that the field still was very much 79 00:04:24,000 --> 00:04:27,520 in a development comparison mode. 80 00:04:27,600 --> 00:04:30,360 There were a large number of studies that were highlighted about 81 00:04:30,360 --> 00:04:32,160 comparing this method to that method. 82 00:04:32,400 --> 00:04:38,800 And so my take was that while there was this shift and it was driven 83 00:04:38,800 --> 00:04:44,710 by people who were really super users of the technology and 84 00:04:44,710 --> 00:04:49,030 were working very closely with biologists and clinicians, I agree 85 00:04:49,030 --> 00:04:52,470 with you that that was maybe about 25% of what. 86 00:04:52,550 --> 00:04:53,350 What was there. 87 00:04:53,750 --> 00:04:57,670 And then they're probably, I think in your characterization, about 88 00:04:57,670 --> 00:04:59,110 15% being methods development. 89 00:04:59,430 --> 00:05:01,950 I would, I'd stretch that out a little bit. 90 00:05:01,950 --> 00:05:06,550 I'd say I saw that maybe being 30, 40% being methods development. 91 00:05:07,110 --> 00:05:08,230 And then there was a. 92 00:05:09,130 --> 00:05:13,650 Another 30% in the middle where it was pushing the boundaries 93 00:05:13,650 --> 00:05:19,450 of a method a little bit and then using it towards a biological 94 00:05:19,450 --> 00:05:22,490 question, even if they weren't completing the biological question. 95 00:05:23,530 --> 00:05:23,890 Yeah. 96 00:05:23,890 --> 00:05:30,330 I think the trend of applying to technologies in the fields of 97 00:05:31,450 --> 00:05:34,890 precision medicine or in general translational proteomics, 98 00:05:34,890 --> 00:05:39,330 as we call that, I think that evolution has started many years 99 00:05:39,330 --> 00:05:39,610 ago. 100 00:05:39,850 --> 00:05:43,350 I just thought, which is much stronger, much more visible, this 101 00:05:43,430 --> 00:05:45,030 hoopoe than I had seen before. 102 00:05:45,430 --> 00:05:45,830 Yeah. 103 00:05:45,830 --> 00:05:51,430 I also think this hupo made a very strong effort to reach out beyond 104 00:05:51,430 --> 00:05:53,510 the human population. 105 00:05:53,590 --> 00:05:57,750 We saw this in our chat with Jennifer Keddes McAllister where 106 00:05:57,830 --> 00:06:02,870 she shared about this one health concept where you're looking 107 00:06:02,870 --> 00:06:05,670 at agriculture, you're looking at crop science. 108 00:06:05,910 --> 00:06:11,340 And that was very evident for me at World Hoopoe this year, that 109 00:06:11,420 --> 00:06:14,700 there was a reach much further than just human. 110 00:06:15,580 --> 00:06:17,980 Yeah, in fact, I almost forgot about that. 111 00:06:17,980 --> 00:06:20,820 And in fact, I very much appreciated those sessions that went 112 00:06:20,820 --> 00:06:26,660 beyond the human proteome, but looked into adjacent fields in the 113 00:06:26,660 --> 00:06:27,580 agriculture field. 114 00:06:27,580 --> 00:06:31,620 In fact, the presentation, one of the plenary presentations on honeybees 115 00:06:31,620 --> 00:06:34,700 was actually really eye opening in that context. 116 00:06:35,350 --> 00:06:35,630 Absolutely. 117 00:06:35,630 --> 00:06:40,630 And I think that concept that we as humans are part of larger ecosystems 118 00:06:40,950 --> 00:06:45,870 and that the anti fungal agents that we give to our crops 119 00:06:45,870 --> 00:06:49,590 have an impact on our system and our ability to defend against 120 00:06:49,590 --> 00:06:50,630 funguses, for instance. 121 00:06:50,630 --> 00:06:56,550 And so that that human, in the middle of a much larger set of things 122 00:06:56,630 --> 00:07:00,430 was, was really exciting to see for me and exciting to learn 123 00:07:00,430 --> 00:07:00,710 about. 124 00:07:02,360 --> 00:07:06,560 So did you see any new trends or new developments that you want 125 00:07:06,560 --> 00:07:07,240 to share here? 126 00:07:07,560 --> 00:07:12,520 Probably the largest surprise for me was hearing the word proteoform 127 00:07:12,920 --> 00:07:14,120 as much as I did. 128 00:07:14,840 --> 00:07:19,880 It felt to me and I recognize that I'm knee deep in thinking about 129 00:07:19,880 --> 00:07:22,280 proteoforms from the work we're doing at Nautilus. 130 00:07:22,360 --> 00:07:27,840 But despite that, I heard more people talking about proteoforms 131 00:07:27,840 --> 00:07:31,120 as an important thing to look at, as an important thing to measure 132 00:07:31,120 --> 00:07:33,460 as a driver of protein interactions. 133 00:07:33,620 --> 00:07:39,220 I think there were some papers earlier this year where we groups 134 00:07:39,220 --> 00:07:43,540 looked at different splice variants and different PTMs and those 135 00:07:43,620 --> 00:07:47,420 actually completely changing the set of proteins that were interacted 136 00:07:47,420 --> 00:07:47,700 with. 137 00:07:48,180 --> 00:07:54,460 And so for me my major take home was that this transition to 138 00:07:54,460 --> 00:07:58,980 awareness and interest in proteoforms really took off this 139 00:07:58,980 --> 00:07:59,300 year. 140 00:07:59,540 --> 00:08:04,340 I hadn't seen, there was always interest work from people 141 00:08:04,340 --> 00:08:09,340 doing top down or native Ms. And but I think this year I saw just 142 00:08:09,340 --> 00:08:10,940 so much more of it everywhere. 143 00:08:11,820 --> 00:08:13,660 Yeah, maybe I would phrase it differently. 144 00:08:13,660 --> 00:08:17,820 I think, I think I saw the terminology of protoform or proteform 145 00:08:17,820 --> 00:08:24,940 groups escaping the top down field and being discussed in more 146 00:08:24,940 --> 00:08:25,580 general terms. 147 00:08:25,580 --> 00:08:25,820 Right. 148 00:08:25,820 --> 00:08:27,660 What does it mean to detect a protein? 149 00:08:27,660 --> 00:08:31,100 Well, maybe we should be more specific about the real functional 150 00:08:31,100 --> 00:08:34,870 form that we are interested in and obviously that's the proteform. 151 00:08:35,430 --> 00:08:41,510 So it was still a very small, you know, small number of presentations 152 00:08:41,510 --> 00:08:41,790 there. 153 00:08:41,790 --> 00:08:45,510 But I think what I agree with you that those were highly attended 154 00:08:45,590 --> 00:08:49,070 and people were very interested in that as, you know, 155 00:08:49,070 --> 00:08:50,870 the next frontier in proteomics. 156 00:08:51,670 --> 00:08:56,150 I think what's, what's missing in the conversation of the proteform 157 00:08:56,150 --> 00:08:59,630 is the connection to the function and I think that's what 158 00:08:59,630 --> 00:09:02,340 people are, you know, interested in. 159 00:09:03,380 --> 00:09:05,780 And of course that takes more than just a measurement. 160 00:09:05,780 --> 00:09:10,780 It usually takes a bigger study, it takes more context and 161 00:09:10,780 --> 00:09:13,420 I think that's what's going to be, you know, evolving over the next, 162 00:09:13,420 --> 00:09:17,380 you know, many, many years that people have the ability to measure 163 00:09:17,380 --> 00:09:20,700 more of the protein farms they're interested in and then get 164 00:09:20,700 --> 00:09:22,020 that functional context. 165 00:09:22,500 --> 00:09:23,020 Absolutely. 166 00:09:23,020 --> 00:09:27,240 I think, I think there's an awareness and Neil has been promoting 167 00:09:27,240 --> 00:09:30,480 for a long time that we need to have an atlas of proteform so 168 00:09:30,480 --> 00:09:32,320 we even know what's out there right now. 169 00:09:32,320 --> 00:09:34,720 We don't even really know what the universe looks like. 170 00:09:34,720 --> 00:09:36,880 We just think it is impossibly vast. 171 00:09:37,520 --> 00:09:42,120 And so taking that one step further and saying, all right, not 172 00:09:42,120 --> 00:09:44,000 only asking the question what's there? 173 00:09:44,320 --> 00:09:46,480 But how does it functionally contribute? 174 00:09:46,720 --> 00:09:51,680 Does it have a different, does this particular form with these combinations 175 00:09:51,680 --> 00:09:54,600 of modifications have a different enzymatic activity or it 176 00:09:54,600 --> 00:09:56,480 binds to proteins at a different rate? 177 00:09:57,280 --> 00:10:02,020 Those functional down downstream questions have been looked 178 00:10:02,020 --> 00:10:06,700 at by cell signaling people and biophysicists for a long time. 179 00:10:07,180 --> 00:10:11,260 But bringing scale to that question, I think I just, I saw, 180 00:10:11,260 --> 00:10:14,940 I saw a lot more awareness of getting beyond the peptide. 181 00:10:15,740 --> 00:10:20,580 One other thing I saw that was a little, I think has potential to 182 00:10:20,580 --> 00:10:24,540 be very confusing to folks outside of the field of proteomics, 183 00:10:24,720 --> 00:10:28,950 but was there, it is very clear what the definition of a proteoform 184 00:10:28,950 --> 00:10:29,270 is. 185 00:10:29,270 --> 00:10:32,670 It's clear what the definition of a proteform group is in terms 186 00:10:32,670 --> 00:10:38,270 of proteform being defined by a specific chemical entity that has 187 00:10:38,270 --> 00:10:42,950 a combination of splice variants, truncations and multiple 188 00:10:42,950 --> 00:10:44,470 post translational modifications. 189 00:10:45,670 --> 00:10:48,790 In order to measure a proteoform you really need to look 190 00:10:48,790 --> 00:10:52,020 at the full protein there. 191 00:10:52,420 --> 00:10:57,540 But what we also saw was we saw some people who are looking at 192 00:10:57,540 --> 00:11:03,580 one PTM site for instance, and both in targeted immunoassays as 193 00:11:03,580 --> 00:11:06,979 well as in mass spectrometry and then saying, oh, we're measuring 194 00:11:06,979 --> 00:11:07,940 proteoforms. 195 00:11:08,580 --> 00:11:11,140 No, you're measuring post translational modifications. 196 00:11:11,300 --> 00:11:13,060 That's important, that's valuable. 197 00:11:13,380 --> 00:11:17,940 But that is not the same as measuring the full proteoform or 198 00:11:17,940 --> 00:11:18,980 the proteform group. 199 00:11:19,140 --> 00:11:24,720 And just from a nomenclature standpoint, right now that's already 200 00:11:24,720 --> 00:11:26,400 a little confusing within the field. 201 00:11:26,640 --> 00:11:29,960 And I can only imagine to biologists not in the field that 202 00:11:29,960 --> 00:11:34,000 if we're not careful with our language that, that, that could, 203 00:11:34,000 --> 00:11:36,079 could really, really confuse people. 204 00:11:36,880 --> 00:11:41,440 Certainly some more education to do in that respect, people using 205 00:11:41,600 --> 00:11:43,200 or utilizing the terminology. 206 00:11:43,600 --> 00:11:46,640 But I think that will come as more and more people are focusing 207 00:11:46,680 --> 00:11:49,790 on, on this way of approaching proteins. 208 00:11:50,350 --> 00:11:50,750 Right? 209 00:11:51,310 --> 00:11:52,030 Absolutely. 210 00:11:52,030 --> 00:11:57,070 And just recognizing what the, what the advantages and limitations 211 00:11:57,070 --> 00:12:00,510 are of each of the different technologies in terms of their ability 212 00:12:00,510 --> 00:12:02,910 to measure things like CO occurring PTMs. 213 00:12:03,630 --> 00:12:08,350 That simply isn't something that can typically be done with a 214 00:12:08,350 --> 00:12:13,430 standard immunoassay or even a digested protein. 215 00:12:13,430 --> 00:12:17,960 Where we're looking again at peptides, we, we may every now and 216 00:12:17,960 --> 00:12:22,040 again get lucky and have two phosphocytes on the same tryptic 217 00:12:22,040 --> 00:12:25,120 peptide, but that's certainly not the norm. 218 00:12:25,120 --> 00:12:28,800 And if we want to look at multiple PTMs that are very far away 219 00:12:28,800 --> 00:12:33,520 from each other, they will not show up on the same peptidic fragment. 220 00:12:33,520 --> 00:12:37,640 So just as a field, there's a little bit of as this is growing 221 00:12:37,640 --> 00:12:41,680 in awareness, this is growing in conversation and parlance, how 222 00:12:41,680 --> 00:12:44,610 can we make sure that, that we're each talking about the same 223 00:12:44,610 --> 00:12:44,930 thing? 224 00:12:45,410 --> 00:12:45,810 Agree. 225 00:12:47,570 --> 00:12:48,770 What else did you notice? 226 00:12:49,890 --> 00:12:54,050 Well, a second big theme was a continuation of what we discussed, 227 00:12:54,370 --> 00:12:57,570 you know, earlier this year, but also last year, which is the, 228 00:12:58,130 --> 00:13:02,130 you know, the terminology of, you know, multi omics, the approach 229 00:13:03,330 --> 00:13:09,100 to take several technologies or several measuring modalities and 230 00:13:09,100 --> 00:13:12,100 essentially contextualize the results that you have obtained with 231 00:13:12,100 --> 00:13:16,740 proteomics so you understand more about the results that you have 232 00:13:16,740 --> 00:13:20,140 created in terms of biological functions. 233 00:13:20,780 --> 00:13:24,300 And so that's trend, I think that's a multi year trend that continues. 234 00:13:24,940 --> 00:13:28,660 And in that context, I think there's two things that are responsible 235 00:13:28,660 --> 00:13:29,180 for that. 236 00:13:29,820 --> 00:13:37,190 One is certainly that from a vendor perspective, the vendors now 237 00:13:38,070 --> 00:13:43,110 provide instrumentation and methods that are much more integrated, 238 00:13:43,670 --> 00:13:47,390 but they're also standardized to the point where you don't spend 239 00:13:47,390 --> 00:13:52,070 a lot of time optimizing, for example, your LC gradient, you simply 240 00:13:52,070 --> 00:13:55,310 walk up and tell the instrument you want to do 20 runs 241 00:13:55,310 --> 00:13:59,270 per day and then everything is optimized for you and you move on. 242 00:13:59,270 --> 00:14:02,470 Or for affinity based methods, you just say, here's the targets 243 00:14:02,470 --> 00:14:03,270 I'm interested in. 244 00:14:04,010 --> 00:14:05,770 I need to run 500 samples. 245 00:14:06,730 --> 00:14:12,970 The vendors have done their part of providing a more standardized 246 00:14:13,770 --> 00:14:17,290 readout so customers don't spend a lot of time optimizing methods 247 00:14:17,290 --> 00:14:21,530 for it to get an optimized method that enables now researchers 248 00:14:21,530 --> 00:14:24,410 to do more experiments utilizing different technologies. 249 00:14:25,450 --> 00:14:28,850 I think that's part of the multi year trend we're going to observe 250 00:14:28,850 --> 00:14:32,790 where you now have the opportunity, a whole set of tools 251 00:14:32,790 --> 00:14:35,350 to actually dive deep into biology. 252 00:14:36,150 --> 00:14:36,950 That's interesting. 253 00:14:37,110 --> 00:14:41,710 So clearly I am a multiomics researcher and have been for a very 254 00:14:41,710 --> 00:14:44,310 long time, so I'm excited to see this, this trend grow. 255 00:14:45,430 --> 00:14:48,150 Do you think that this is coming from? 256 00:14:49,110 --> 00:14:52,710 So what you alluded to as the rationale for why this is growing 257 00:14:52,950 --> 00:14:56,630 is that the toolkit of proteomics is becoming more accessible. 258 00:14:57,830 --> 00:15:00,630 To what extent do you think this is coming from the other side, 259 00:15:01,030 --> 00:15:05,350 where we have folks who are traditionally genomics researchers 260 00:15:06,550 --> 00:15:09,910 feeling bottlenecked or like there's a barrier in their ability 261 00:15:09,910 --> 00:15:14,190 to convert what their findings are to biological consequence and 262 00:15:14,190 --> 00:15:19,390 that there's a need for the Protein layer to be part of those 263 00:15:19,390 --> 00:15:20,710 full functional models. 264 00:15:21,670 --> 00:15:22,910 That's an interesting question. 265 00:15:22,910 --> 00:15:28,280 I think what I sense is that the initial vision of proteomics, 266 00:15:28,360 --> 00:15:30,240 which was very similar to genomics, right? 267 00:15:30,240 --> 00:15:32,400 You've got to be able to just do the whole proteome. 268 00:15:32,400 --> 00:15:35,080 You got to do it in half the time and one third of the cost. 269 00:15:35,160 --> 00:15:39,000 So this, this type of technology mindset has basically, 270 00:15:39,320 --> 00:15:40,439 you know, disappeared. 271 00:15:40,439 --> 00:15:45,040 It's now much more about I need to be able to understand functional 272 00:15:45,040 --> 00:15:45,640 biology. 273 00:15:45,640 --> 00:15:49,240 And that means I need more than one tool because, you know, 274 00:15:49,320 --> 00:15:52,760 any tool set is limited given the complexity of the proteome. 275 00:15:52,840 --> 00:15:56,620 And I think that's what drives it, that everybod understands. 276 00:15:56,620 --> 00:16:00,580 I can only observe a sub portion of my science. 277 00:16:00,580 --> 00:16:03,180 If I use one tool, I need to use several tools. 278 00:16:03,180 --> 00:16:06,340 And I think that's what drives the multi omics. 279 00:16:06,420 --> 00:16:10,500 And I think multi omics maybe gets a little bit overextended. 280 00:16:10,740 --> 00:16:15,140 It's not just multiple modalities, but it's just multiple 281 00:16:15,140 --> 00:16:18,580 methods that often uses the terminology multi omics. 282 00:16:18,580 --> 00:16:23,100 So in that context, maybe multi omics is broader than initially 283 00:16:23,100 --> 00:16:23,700 discussed. 284 00:16:24,310 --> 00:16:28,510 Yeah, I guess my question was more about do you see that the push 285 00:16:28,510 --> 00:16:33,670 into multiomics is proteomics people moving closer to genomics 286 00:16:33,670 --> 00:16:38,630 and incorporating genomics in their studies or is it more genomics 287 00:16:38,630 --> 00:16:42,110 people moving closer to proteomics and incorporating proteomics 288 00:16:42,110 --> 00:16:42,790 in their studies? 289 00:16:43,350 --> 00:16:44,550 I think I see both. 290 00:16:44,550 --> 00:16:49,710 I mean, some vendors or some platforms utilizing more, you know, 291 00:16:49,710 --> 00:16:52,750 proteomic nucleic acid amplification type approaches. 292 00:16:52,750 --> 00:16:56,390 So you might get people from the genomics field familiar with 293 00:16:56,390 --> 00:16:59,790 the technology of PCR or next generation sequencing, saying, hey, 294 00:16:59,790 --> 00:17:02,510 I can extend now my measurement, my tech tool set that 295 00:17:02,510 --> 00:17:05,150 I already know very well into the proteomics space. 296 00:17:05,150 --> 00:17:08,590 And then they basically have access through these methods into 297 00:17:08,590 --> 00:17:09,430 the proteomics. 298 00:17:09,430 --> 00:17:11,030 And I think that's happening in parallel. 299 00:17:11,030 --> 00:17:16,430 While the proteomics tools are solid enough, high resolution enough, 300 00:17:16,510 --> 00:17:21,260 fast enough to create many observations that essentially cannot 301 00:17:21,260 --> 00:17:24,940 be really well understood until, unless you contextualize it 302 00:17:24,940 --> 00:17:25,980 with other modalities. 303 00:17:26,460 --> 00:17:27,700 Interesting, interesting. 304 00:17:27,700 --> 00:17:32,300 Yeah, I think one of my takeaways I think is related. 305 00:17:32,700 --> 00:17:37,900 I guess I was aiming to have three takeaways for the year. 306 00:17:38,060 --> 00:17:39,500 I ended up with four. 307 00:17:39,820 --> 00:17:42,460 But two of them are very close to each other. 308 00:17:42,460 --> 00:17:48,030 So one of my big takeaways was really experiment size that and, 309 00:17:48,110 --> 00:17:50,430 and scale of experimentation. 310 00:17:50,990 --> 00:17:57,790 This year I saw a larger number of large scale, thousands 311 00:17:57,790 --> 00:18:02,510 of sample studies, tens of thousands of sample studies in proteomics. 312 00:18:02,590 --> 00:18:07,910 There was the, the work that Sarah Hadi published earlier in the 313 00:18:07,910 --> 00:18:13,750 year where she did a multi, a multi platform comparison across 314 00:18:13,750 --> 00:18:14,750 thousands of samples. 315 00:18:14,750 --> 00:18:20,150 We had UK biobank studies, we had another study that was, was promoted 316 00:18:20,150 --> 00:18:24,190 again on the scale of that is getting off the ground, aiming to 317 00:18:24,190 --> 00:18:27,270 measure potentially a million samples by proteomics. 318 00:18:27,750 --> 00:18:33,870 And so that just that concept of experimentation on that, on that 319 00:18:33,870 --> 00:18:38,870 order, I saw so much more this year than I had in previous years. 320 00:18:40,070 --> 00:18:45,830 But the, the flip side of that was I can't tell whether it is a 321 00:18:45,830 --> 00:18:50,590 small number of people who have done these massive, massive 322 00:18:50,590 --> 00:18:54,990 studies and whether that's the whole field is shifting towards things 323 00:18:54,990 --> 00:18:59,070 needing to be on that scale or if it's just it has become more possible 324 00:18:59,230 --> 00:19:03,470 for those, those, those couple, couple people to do things 325 00:19:03,470 --> 00:19:04,270 on that scale. 326 00:19:05,310 --> 00:19:06,510 Interesting observation. 327 00:19:06,590 --> 00:19:10,550 I think it aligns a little bit what I, you know, sort of mentioned 328 00:19:10,550 --> 00:19:13,830 with the multiomics, that it basically is a multiple platform 329 00:19:13,830 --> 00:19:15,550 discipline, proteomics now. 330 00:19:17,030 --> 00:19:19,790 And I agree with you, I think there's not a lot of laboratories 331 00:19:19,790 --> 00:19:24,990 that actually are capable of very large studies because it entails 332 00:19:24,990 --> 00:19:27,190 more than just access to the platform. 333 00:19:27,190 --> 00:19:32,110 It entails experimental design, the biostatistics, in the 334 00:19:32,110 --> 00:19:36,790 end access to a particular sample site, whether it's biobank 335 00:19:36,790 --> 00:19:37,670 sample or other. 336 00:19:38,150 --> 00:19:46,680 So it's probably the fact that there's more focus around these type 337 00:19:46,680 --> 00:19:48,440 of projects enabled by technology. 338 00:19:49,160 --> 00:19:52,160 I'm not sure this is yet mainstream that every laboratory 339 00:19:52,160 --> 00:19:53,840 is planning to do these type of studies. 340 00:19:53,840 --> 00:19:59,760 But certainly I saw more posters with n equals 1000, n equals 341 00:19:59,760 --> 00:20:03,640 1, which used to be pretty much the standard 20 years ago. 342 00:20:04,040 --> 00:20:05,120 Yeah, yeah, absolutely. 343 00:20:05,120 --> 00:20:12,010 So I think for me this takeaway in scale and this growing 344 00:20:12,410 --> 00:20:16,490 desire for larger scale proteomics was something I observed. 345 00:20:16,570 --> 00:20:21,690 I think that goes hand in hand with something that is of course 346 00:20:21,690 --> 00:20:24,490 top of mind in the world, which is AI. 347 00:20:25,050 --> 00:20:31,330 And how as we think about proteomics, there's now a HUPO AI 348 00:20:31,330 --> 00:20:35,050 readiness group that is working on developing standards for, 349 00:20:35,660 --> 00:20:38,860 for proteomics to interact with AI tooling. 350 00:20:39,180 --> 00:20:45,500 There have been some folks building foundation models in proteomics 351 00:20:45,500 --> 00:20:48,460 to complement foundation models in genomics. 352 00:20:49,020 --> 00:20:56,620 And so I think that rise of studies incorporating late stage 353 00:20:56,620 --> 00:21:00,700 proteomics data into their, into their AI models is growing a 354 00:21:00,700 --> 00:21:00,940 lot. 355 00:21:01,260 --> 00:21:04,940 And just to clarify what I mean by late stage proteomics data, 356 00:21:05,180 --> 00:21:09,590 what I'm really referring to is where in the integration process 357 00:21:09,990 --> 00:21:12,070 is the proteomics data brought in. 358 00:21:12,550 --> 00:21:16,070 So there are different types of models where there's early integration, 359 00:21:16,150 --> 00:21:19,710 middle integration, late integration and early integration 360 00:21:19,710 --> 00:21:25,550 might be all the way starting from RNA SEQ data, raw reads being 361 00:21:25,550 --> 00:21:31,910 integrated at the spectra level to interpret the Actual spectra 362 00:21:32,070 --> 00:21:35,710 coming in and the actual primary data that comes out of that 363 00:21:35,710 --> 00:21:37,670 for subsequent analysis. 364 00:21:37,830 --> 00:21:40,930 That's early stage integration where you're, you're integrating 365 00:21:40,930 --> 00:21:44,210 all the different data in the earliest part of the process. 366 00:21:44,850 --> 00:21:48,210 Late stage integration, on the other hand, says we're going to take 367 00:21:48,210 --> 00:21:53,170 the simplest raw, the simplest, least raw, most processed 368 00:21:53,170 --> 00:21:57,490 outputs, protein abundances and quants, possibly after having 369 00:21:57,490 --> 00:22:03,610 been imputed, and merge those together with the again post processed 370 00:22:03,610 --> 00:22:07,970 RNA SEQ FPKM values that have already been cleaned up and normalized 371 00:22:07,970 --> 00:22:12,800 and potentially already looked at for which features are separated. 372 00:22:13,280 --> 00:22:19,800 So it really, I haven't seen as much of proteomics data and other 373 00:22:19,800 --> 00:22:24,320 OHMS data being brought in together at the raw data stage. 374 00:22:24,400 --> 00:22:29,880 It really has been at much later once you already have quants 375 00:22:29,880 --> 00:22:33,680 and maybe even already have differences between each of them. 376 00:22:34,480 --> 00:22:39,400 And one of the potential benefits of, of moving earlier and 377 00:22:39,400 --> 00:22:42,240 doing early integration instead of late integration is that 378 00:22:42,240 --> 00:22:44,800 you might find things, for instance, there might be mutations 379 00:22:45,200 --> 00:22:49,520 that are found in the RNA SEQ data or the DNA SEQ data that can 380 00:22:49,520 --> 00:22:54,240 then go into the proteogenomic workflow to validate that those protein 381 00:22:54,240 --> 00:22:57,360 products are actually translated ones that contain those 382 00:22:57,360 --> 00:22:57,920 mutations. 383 00:22:58,400 --> 00:23:05,340 You also might be able to do a better job of interpreting with the 384 00:23:05,340 --> 00:23:08,420 full data cube as opposed to just, hey, These are the 20 proteins 385 00:23:08,420 --> 00:23:11,340 that are different or the 20 transcripts that are different in 386 00:23:11,340 --> 00:23:11,980 the RNA data. 387 00:23:11,980 --> 00:23:13,820 These are the 20 proteins that are different. 388 00:23:14,140 --> 00:23:18,420 You could look at how the, how the entire collection across the 389 00:23:18,420 --> 00:23:22,300 whole system is changing from the transcript level to the protein 390 00:23:22,300 --> 00:23:22,620 level. 391 00:23:22,780 --> 00:23:26,700 So there are sets of questions that are best answered by early integration. 392 00:23:26,940 --> 00:23:31,700 But the data volumes are larger, the complexity of the analysis 393 00:23:31,700 --> 00:23:32,860 is substantially larger. 394 00:23:33,200 --> 00:23:36,480 The domain knowledge that's required to do that is significantly 395 00:23:36,480 --> 00:23:37,040 larger. 396 00:23:37,360 --> 00:23:39,640 So that's probably why most people don't do it. 397 00:23:39,640 --> 00:23:42,800 But there are some major, major benefits to doing so. 398 00:23:43,280 --> 00:23:48,160 The other place where AI was having an influence was inside so 399 00:23:48,160 --> 00:23:52,120 doing things like looking over spectral libraries to do a better 400 00:23:52,120 --> 00:23:54,640 job of identifying peptides, for instance. 401 00:23:55,040 --> 00:23:59,540 So I think we are seeing AI creep into the ecosystem and not 402 00:23:59,540 --> 00:24:04,140 just be a consumer at the tail end of proteomics. 403 00:24:04,460 --> 00:24:08,540 Yeah, maybe, you know, to the, to the topic of AI, I think I saw 404 00:24:08,540 --> 00:24:14,020 actually less posters on AI, but I think the observation that 405 00:24:14,020 --> 00:24:17,580 AI is now part of proteomics is absolutely correct. 406 00:24:18,060 --> 00:24:22,700 I think we saw the big, you know, hello world of AI in proteomics 407 00:24:22,700 --> 00:24:26,700 in 2024 and I think, you know, saw probably less representation 408 00:24:26,700 --> 00:24:30,500 of it, but people are seriously incorporating them. 409 00:24:30,500 --> 00:24:34,220 In fact, I saw a poster from The Matthias Mann lab, where they 410 00:24:34,220 --> 00:24:38,940 essentially trained AI to learn all about the mistakes you 411 00:24:38,940 --> 00:24:42,900 can make, hoping that the next person who is going to use the platform 412 00:24:43,780 --> 00:24:49,700 is not making the mistakes and is in fact not wasting a sample because 413 00:24:49,700 --> 00:24:51,100 they know they're not ready for it. 414 00:24:51,100 --> 00:24:53,820 And so I think that these are very interesting developments and 415 00:24:53,820 --> 00:24:57,440 certainly on the spectral side, I think, think we all can agree 416 00:24:57,440 --> 00:25:00,160 that machines are going to be much better reading spectra than 417 00:25:00,160 --> 00:25:04,800 humans will ever be, given the volumes that these instruments today 418 00:25:04,960 --> 00:25:05,600 generate. 419 00:25:07,040 --> 00:25:11,760 I think just carrying that out, one of the, this segues into 420 00:25:11,760 --> 00:25:15,600 my last big observation from the year and then I'll ask you about 421 00:25:15,600 --> 00:25:19,200 your last observation in the year, which is really about quality. 422 00:25:19,920 --> 00:25:25,790 And this is a place where I am both optimistic and concerned at 423 00:25:25,790 --> 00:25:30,310 the same time because these, as you said, there are a lot more 424 00:25:30,310 --> 00:25:34,590 people who are pressing the go button and generating DIA spectra 425 00:25:34,590 --> 00:25:38,950 and taking whatever the software tools come out and say, 426 00:25:38,950 --> 00:25:42,150 oh, this is how much of this protein is there based on this peptide 427 00:25:42,150 --> 00:25:42,670 roll up. 428 00:25:42,830 --> 00:25:46,430 And those folks often do have a deep understanding that hey, I 429 00:25:46,430 --> 00:25:51,380 need to look at six daughter ions, I can't just look at one in 430 00:25:51,380 --> 00:25:54,460 order to be confident in a protein identification. 431 00:25:54,940 --> 00:26:00,140 But then that identification leading to a protein group which 432 00:26:00,140 --> 00:26:04,700 may have multiple proteins associated with it, how that then 433 00:26:04,700 --> 00:26:10,180 gets boiled down to a single protein that says, hey, this is how 434 00:26:10,180 --> 00:26:12,380 much of this single protein is there. 435 00:26:14,020 --> 00:26:16,740 There's, there's a chain, there's a tree, there's some complexity 436 00:26:16,740 --> 00:26:21,940 there that is, that is getting lost in the translation to a very 437 00:26:21,940 --> 00:26:25,060 simple table of this is the protein and this is how much is there 438 00:26:25,460 --> 00:26:29,540 that is used as the input for many other downstream analyses. 439 00:26:30,180 --> 00:26:33,900 So there's, there's a little bit of a, an excitement that the 440 00:26:33,900 --> 00:26:38,980 field is having awareness about the need for improving quality 441 00:26:39,810 --> 00:26:45,890 and recognizing that not all protein quantification data is equal. 442 00:26:46,530 --> 00:26:51,330 But on the other hand, I didn't see a clear set of solutions 443 00:26:51,410 --> 00:26:56,210 emerging to deal with the diversity of different types of proteomic 444 00:26:56,210 --> 00:27:02,050 workflows, proteomics data, whether it's TMT data or DIA MS.1 445 00:27:02,050 --> 00:27:08,280 data or Spectral counting data or data from an affinity based platform, 446 00:27:08,840 --> 00:27:15,000 how we treat those all in common so that we can understand 447 00:27:15,160 --> 00:27:17,160 what are the quality aspects of the data. 448 00:27:18,120 --> 00:27:23,960 Again, I saw a greater awareness of this as a field, but 449 00:27:24,200 --> 00:27:27,240 didn't see any major solutions coming forwards. 450 00:27:28,520 --> 00:27:33,560 Yeah, I mean, I was also not seeing any solutions to the topic 451 00:27:33,560 --> 00:27:34,440 you addressed here. 452 00:27:35,310 --> 00:27:39,070 I think there's always going to be as part of the method development, 453 00:27:39,950 --> 00:27:42,830 instrument development efforts, people who push the boundaries, 454 00:27:42,990 --> 00:27:47,230 but I am getting less and less concerned about it as we move forward. 455 00:27:47,550 --> 00:27:53,990 Given that I see proteomics as a multi platform approach that if 456 00:27:53,990 --> 00:27:56,910 you're really interested in a target, you will get several ways 457 00:27:56,910 --> 00:27:58,350 to confirm your observations. 458 00:27:59,470 --> 00:28:05,230 And so even if one platform gets it wrong or is not as confident 459 00:28:05,230 --> 00:28:09,110 as measurement, I think applying a second or third tool will 460 00:28:09,110 --> 00:28:10,870 ultimately flush out the truth. 461 00:28:11,670 --> 00:28:15,430 It's just the part that's concerning is some of the experiments 462 00:28:15,430 --> 00:28:19,910 are very time consuming, whether it's a large study or it's 463 00:28:19,910 --> 00:28:21,950 an expensive experiment. 464 00:28:21,950 --> 00:28:27,390 And so you might not want to spend a lot of energy on chasing 465 00:28:27,390 --> 00:28:32,490 a target that you created with a very, very expensive approach and 466 00:28:32,490 --> 00:28:35,890 then find later out that it is not a viable target. 467 00:28:36,290 --> 00:28:39,730 And so in that sense I share a concern that we need to continue 468 00:28:39,890 --> 00:28:42,370 to make sure that we know what we're looking at. 469 00:28:43,410 --> 00:28:47,330 Define what quality means, define what protein ID means. 470 00:28:47,330 --> 00:28:51,290 And I think that goes back to just the conversation we just had 471 00:28:51,290 --> 00:28:52,170 around Proteform. 472 00:28:52,170 --> 00:28:57,810 Right now, Proteform might be a terminology you easily throw around, 473 00:28:57,890 --> 00:29:02,060 but when it comes down to naming the proteform, we better be 474 00:29:02,060 --> 00:29:06,420 very clear and have a solid identification for the solid proof 475 00:29:06,420 --> 00:29:07,060 points for it. 476 00:29:07,300 --> 00:29:13,900 Yeah, I saw a study earlier this year where in the study they 477 00:29:13,900 --> 00:29:17,060 were very excitedly commenting on that. 478 00:29:17,139 --> 00:29:22,420 I think it was 60% of their quantifications had CVs below 30% 479 00:29:23,620 --> 00:29:28,420 and it was something on that order like, wow, all right, well 480 00:29:29,250 --> 00:29:31,850 what about the rest of the data and how should we think about 481 00:29:31,850 --> 00:29:39,450 it if the CVs are 100 or 200% and do we know that for most data 482 00:29:39,450 --> 00:29:41,730 sets and in many cases the answer is no. 483 00:29:42,290 --> 00:29:46,130 So the fact that some protein IDs might be extremely confident, 484 00:29:46,130 --> 00:29:50,290 they might be extremely high quantitation accuracy, very high 485 00:29:50,290 --> 00:29:55,050 precision and other protein measurements in the same data set 486 00:29:55,050 --> 00:29:55,810 may not be. 487 00:29:56,310 --> 00:30:02,910 I think that's something that is not well captured yet, but is 488 00:30:02,910 --> 00:30:06,150 an opportunity as a field for us to improve on. 489 00:30:06,470 --> 00:30:09,750 So Andreas, what was your final takeaway from the year? 490 00:30:10,310 --> 00:30:14,310 Well, final takeaway was that certain things that I didn't observe. 491 00:30:15,350 --> 00:30:19,150 So for example, I was surprised that we didn't see more 492 00:30:19,150 --> 00:30:20,470 spatial proteomics. 493 00:30:20,790 --> 00:30:23,980 That was a buzzword just two years ago. 494 00:30:24,700 --> 00:30:28,420 And so yeah, there were some posters using very sophisticated 495 00:30:28,420 --> 00:30:29,660 multi imaging system now. 496 00:30:29,660 --> 00:30:35,020 I mean they're really improving in resolution and certainly 497 00:30:35,180 --> 00:30:40,660 people make a lot of effort to look at biology relevant answers 498 00:30:40,660 --> 00:30:42,540 in these spatial efforts. 499 00:30:42,780 --> 00:30:47,260 But I was surprised given all of the buzz around the technology 500 00:30:47,580 --> 00:30:50,460 that's been evolving the last 10 years and quite frankly the investment 501 00:30:50,540 --> 00:30:54,500 has been made in the field that we didn't see a lot more spatial 502 00:30:54,500 --> 00:30:57,160 proteom results there. 503 00:30:57,240 --> 00:31:02,880 So it might be the fact that maybe the HUPO meeting is not the 504 00:31:02,880 --> 00:31:05,240 meeting that is focused typically on that. 505 00:31:05,640 --> 00:31:10,040 But I would hope that in the future we'll see more of these technologies 506 00:31:10,040 --> 00:31:13,600 that are, you know, have spatial resolution that they actually 507 00:31:13,600 --> 00:31:16,280 also join, you know, the, the HUPO conference. 508 00:31:16,840 --> 00:31:17,840 Yeah, absolutely. 509 00:31:17,840 --> 00:31:19,040 I, I noticed the same thing. 510 00:31:19,040 --> 00:31:23,980 I, I was expecting there to be this onslaught of spatial and single 511 00:31:23,980 --> 00:31:29,660 cell presentations and posters and I was surprised to see a lot 512 00:31:29,660 --> 00:31:30,780 less of that this year. 513 00:31:31,820 --> 00:31:35,260 But clearly over the last several years it was a huge, huge 514 00:31:35,580 --> 00:31:40,660 emphasis and so maybe this is just a slight wiggle and next year 515 00:31:40,660 --> 00:31:42,940 it'll be all single cell and spatial all the time. 516 00:31:42,940 --> 00:31:43,820 We'll find out. 517 00:31:44,460 --> 00:31:48,970 But I also noticed a little bit less, less focus on that area 518 00:31:48,970 --> 00:31:49,490 this year. 519 00:31:50,210 --> 00:31:50,690 Yeah. 520 00:31:50,930 --> 00:31:54,890 So overall my takeaway for the, for, you know, the year but 521 00:31:54,890 --> 00:31:58,210 also for the conference was that preomic's landscape is obviously 522 00:31:58,210 --> 00:32:04,210 consolidating around clinical and translational translational applications 523 00:32:04,930 --> 00:32:09,210 while expanding the multi platform aspect of, and the new innovations 524 00:32:09,210 --> 00:32:09,890 around that. 525 00:32:10,690 --> 00:32:14,810 And I think in general the field is maturing from an instrumentation 526 00:32:14,810 --> 00:32:18,950 driven discovery to workflow that are integrated and focused on 527 00:32:18,950 --> 00:32:19,590 biology. 528 00:32:19,910 --> 00:32:23,790 Well, so I'm going to put you on the spot, Andreas, and ask you 529 00:32:23,790 --> 00:32:26,710 to lock in a prediction for 2026. 530 00:32:29,110 --> 00:32:31,030 A year later we're going to come back to this. 531 00:32:31,030 --> 00:32:36,030 And what are the three things that you're hoping to see, expecting 532 00:32:36,030 --> 00:32:40,230 to see when we do our 2026 wrap up next year? 533 00:32:40,870 --> 00:32:46,270 Well, I would hope to see true applications of AI where we can now 534 00:32:46,270 --> 00:32:50,530 say, look, those spectra are, weren't able to interpret now have 535 00:32:50,530 --> 00:32:56,410 solid evidence or we have a new way to impute missing data, for 536 00:32:56,410 --> 00:32:56,930 example. 537 00:32:57,330 --> 00:33:01,450 So I hope that there is going to be some kind of breakthrough in 538 00:33:01,450 --> 00:33:01,970 this area. 539 00:33:02,210 --> 00:33:06,570 I think the other area I'm really expecting to continue to evolve 540 00:33:06,570 --> 00:33:09,490 is the area we just discussed on proteoforms. 541 00:33:09,890 --> 00:33:13,330 Looking much more at the functional aspect of the proteome. 542 00:33:13,650 --> 00:33:19,380 I think the areas that I see continuously underrepresented structural 543 00:33:19,380 --> 00:33:24,060 biology, chemical chemoproteomics, protein, protein 544 00:33:24,060 --> 00:33:24,620 directions. 545 00:33:24,620 --> 00:33:29,060 I think that these are, these are areas that I hope we will see 546 00:33:29,140 --> 00:33:31,220 many, many more breakthroughs in the future. 547 00:33:31,860 --> 00:33:32,500 That's super. 548 00:33:32,500 --> 00:33:33,140 Thank you. 549 00:33:33,140 --> 00:33:33,820 Thank you very much. 550 00:33:33,820 --> 00:33:39,220 Andreas, what will you, what will be your projections for 2026? 551 00:33:39,860 --> 00:33:42,500 Oh golly, I was hoping just to put you on the spot. 552 00:33:43,460 --> 00:33:49,650 I'm, I'm going to go with, I do think this question of multi omics 553 00:33:49,650 --> 00:33:53,850 and how do we integrate multiple data types is going to continue 554 00:33:53,850 --> 00:33:54,370 to grow. 555 00:33:54,930 --> 00:34:00,369 I think it's clear that there are, there's so much happening at 556 00:34:00,369 --> 00:34:04,210 different scales and the tooling to be able to ask those questions 557 00:34:04,290 --> 00:34:05,490 has gotten a lot better. 558 00:34:05,650 --> 00:34:10,130 So I very much am expecting an expansion in multi omics studies. 559 00:34:10,450 --> 00:34:15,640 I think we also see things like the CPTAC data sets are now 560 00:34:15,800 --> 00:34:17,480 just massive. 561 00:34:17,960 --> 00:34:21,320 The number of cancers they've looked at, the number of different 562 00:34:21,560 --> 00:34:25,560 tissue types and the metadata around those samples is tremendous. 563 00:34:25,880 --> 00:34:28,200 And so I'm anticipating that. 564 00:34:28,280 --> 00:34:31,160 One of the other things we're going to see this coming year alongside 565 00:34:31,160 --> 00:34:34,520 this growth in AI is an increase in data reuse. 566 00:34:35,080 --> 00:34:39,920 Now that we have these massive corpuses of data, some of these larger 567 00:34:39,920 --> 00:34:42,280 clinical studies, these tens of thousands of samples clinical 568 00:34:42,280 --> 00:34:42,680 studies. 569 00:34:43,200 --> 00:34:46,520 I'm looking forward to 2026 having a tremendous amount of data 570 00:34:46,520 --> 00:34:47,200 reuse. 571 00:34:47,680 --> 00:34:52,120 And I think number three, I really do think this connection to 572 00:34:52,120 --> 00:34:56,480 biology and having more and more of these stories come out where 573 00:34:56,640 --> 00:35:02,600 it's so clear that it is that the proteome was a necessary part 574 00:35:02,600 --> 00:35:06,640 of the biological mechanism, I think, I think that's my other hope. 575 00:35:06,640 --> 00:35:08,720 Slash expectation for 2026. 576 00:35:09,890 --> 00:35:12,370 Well, very much looking forward to 2026 then. 577 00:35:14,610 --> 00:35:15,810 Thank you so much, Andreas. 578 00:35:16,290 --> 00:35:18,130 That was a really fun conversation. 579 00:35:18,370 --> 00:35:20,850 Always great to reflect and look back on the year. 580 00:35:21,170 --> 00:35:24,410 And thank you, all of you for joining us to hear our takeaways 581 00:35:24,410 --> 00:35:25,410 from 2025. 582 00:35:25,810 --> 00:35:29,370 Be sure to share your thoughts on Proteomics in 2025 in the comments 583 00:35:29,370 --> 00:35:30,290 and stay tuned. 584 00:35:30,290 --> 00:35:33,970 We've got some really great conversations in the works for 2026. 585 00:35:38,620 --> 00:35:42,260 We hope you enjoyed the Translating Proteomics podcast brought 586 00:35:42,260 --> 00:35:44,300 to you by Nautilus Biotechnology. 587 00:35:44,780 --> 00:35:48,860 To contact us or for further information, please email Translating 588 00:35:48,860 --> 00:35:51,180 Proteomics at Nautilus Bio.